AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published on August 1
These companies are proving that smart research and development can turn potential patent disasters into growth opportunities. When new drugs succeed, the rewards can be massive.
AbbVie's success story shows that pharmaceutical companies with strong pipelines can not only survive patent cliffs but actually thrive. This blueprint could work for others in the group.
Professional analysts handpicked these companies for their ability to navigate one of pharma's biggest challenges. Each represents potential for substantial long-term growth in healthcare.
AbbVie's successful transition from Humira to new blockbusters like Skyrizi and Rinvoq proves that pharmaceutical companies can thrive beyond patent cliffs. This creates opportunities in drugmakers with strong research pipelines that can replace aging products with innovative treatments, positioning them for long-term growth in the healthcare sector.
Patent cliffs occur when blockbuster drugs lose exclusivity, often causing significant revenue declines. However, companies with robust research and development capabilities can navigate this challenge by launching next-generation therapies. This group focuses on resilient pharmaceutical firms with proven or potential ability to manage these critical transitions.
These pharmaceutical companies were handpicked by professional analysts for their promising drug pipelines and demonstrated ability to replace revenues from expiring patents. Each firm represents the potential to unlock substantial growth as new revenue streams mature, making them attractive for long-term healthcare sector investment.
Market capitalisation breakdown for the pharmaceutical-focused basket 'Beyond The Patent Cliff: Pharma's New Growth Engines'.
ABBV: $408.76B
PFE: $141.29B
VRTX: $109.29B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+7
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+3.27%
On average, analysts expect assets in this group to grow 3.27% over the next year.
12 of 16 assets in this group are rated Buy by professional analysts.
